Crane Advisory LLC Has $1.52 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Crane Advisory LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the first quarter, Holdings Channel reports. The institutional investor owned 9,994 shares of the company’s stock after purchasing an additional 169 shares during the period. Johnson & Johnson comprises about 0.3% of Crane Advisory LLC’s portfolio, making the stock its 17th largest holding. Crane Advisory LLC’s holdings in Johnson & Johnson were worth $1,516,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $156.90 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The business has a fifty day moving average price of $153.84 and a 200-day moving average price of $153.70. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market capitalization of $377.52 billion, a P/E ratio of 23.59, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on JNJ. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Raymond James decreased their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Morgan Stanley increased their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Finally, Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.